An update on dengue vaccine development, challenges, and future perspectives

Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study

(2020) Clemente Diaz et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial

(2020) Anna P. Durbin et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial

(2020) Vianney Tricou et al.   LANCET

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

(2020) Shibadas Biswal et al.   LANCET

Relative contribution of nonstructural protein 1 in dengue pathogenesis

(2020) Pei Xuan Lee et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Dengue

(2019) Annelies Wilder-Smith et al.   LANCET

Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy

(2019) Julia A. Brown et al.   IMMUNITY

Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate

(2019) Laura Lazo et al.   Expert Review of Vaccines

A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice

(2019) Claude Roth et al.   Frontiers in Immunology

Mimicking immune signatures of flavivirus infection with targeted adjuvants improves dengue subunit vaccine immunogenicity

(2019) Katell Bidet et al.   npj Vaccines

Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection

(2019) Yu-San Kao et al.   JOURNAL OF IMMUNOLOGY

Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?

(2019) Iris Valdés et al.   Frontiers in Immunology

Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection

(2019) Candice Y. Y. Chan et al.   mSphere

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial

(2018) Janine R. Danko et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Combination and inducible adjuvants targeting nucleic acid sensors

(2018) Burcu Temizoz et al.   CURRENT OPINION IN PHARMACOLOGY

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study

(2018) Xavier Sáez-Llorens et al.   LANCET INFECTIOUS DISEASES

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

(2018) Saranya Sridhar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of a Tetravalent Live-attenuated Dengue Vaccine in Flavivirus Naive Children

(2018) Sriluck Simasathien et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Nanoparticle Delivery of a Tetravalent E Protein Subunit Vaccine Induces Balanced, Type-Specific Neutralizing Antibodies to Each Dengue Virus Serotype

(2018) Stefan W. Metz et al.   PLoS Neglected Tropical Diseases

Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice

(2018) Jinqiu Zhang et al.   BMC Veterinary Research

Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice

(2018) Angela M. Fowler et al.   Cell Host & Microbe

Insights from direct studies on human dengue infections

(2018) Scott B. Halstead   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dengue vaccine: WHO position paper, September 2018 – Recommendations

(2018)   VACCINE

Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-Naïve adults

(2018) Susan B. Manoff et al.   Human Vaccines & Immunotherapeutics

Dengvaxia controversy: impact on vaccine hesitancy

(2018) Khunsha Fatima et al.   Journal of Global Health

Clinical and Laboratory Diagnosis of Dengue Virus Infection

(2017) David A. Muller et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

(2017) Martin Alberer et al.   LANCET

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study

(2017) Xavier Sáez-Llorens et al.   LANCET INFECTIOUS DISEASES

Dengue: knowledge gaps, unmet needs, and research priorities

(2017) Leah C Katzelnick et al.   LANCET INFECTIOUS DISEASES

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity

(2017) Susana V. Bardina et al.   SCIENCE

An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy

(2017) Srinivasa Reddy Bonam et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

A novel combination adjuvant platform for human and animal vaccines

(2017) Ravendra Garg et al.   VACCINE

Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age

(2017) Scott B. Halstead   VACCINE

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination

(2017) Stephen S. Whitehead et al.   PLoS Neglected Tropical Diseases

Dengue Virus Glycosylation: What Do We Know?

(2017) Sally S. L. Yap et al.   Frontiers in Microbiology

Dengue virus compartmentalization during antibody-enhanced infection

(2017) Eugenia Z. Ong et al.   Scientific Reports

Dengue NS1 antigen contributes to disease severity by inducing interleukin (IL)-10 by monocytes

(2016) T. N. Adikari et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef

(2016) Rajesh T. Gandhi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians#

(2016) Emily S. Jentes et al.   JOURNAL OF TRAVEL MEDICINE

Human CD4 + T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity

(2016) Michael A. Angelo et al.   JOURNAL OF VIROLOGY

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus

(2016) Wanwisa Dejnirattisai et al.   NATURE IMMUNOLOGY

Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine

(2016) Monika Simmons et al.   PLoS One

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort

(2016) Leah C. Katzelnick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

(2016) K. Stettler et al.   SCIENCE

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

(2016) Beth D. Kirkpatrick et al.   Science Translational Medicine

Prime-boost vaccine strategy against viral infections: Mechanisms and benefits

(2016) Kimia Kardani et al.   VACCINE

The Good, the Bad, and the Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis

(2016) Dustin R. Glasner et al.   Annual Review of Virology

Plasmablasts During Acute Dengue Infection Represent a Small Subset of a Broader Virus-specific Memory B Cell Pool

(2016) Ramapraba Appanna et al.   EBioMedicine

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

(2016) Niels Peter H. Knudsen et al.   Scientific Reports

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico

(2015) Kristen Bauer et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control

(2015) Michael S. Diamond et al.   CELL

Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?

(2015) Jian Hang Lam et al.   Expert Review of Vaccines

Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

(2015) Stephen S. Whitehead   Expert Review of Vaccines

T cell immunity to dengue virus and implications for vaccine design

(2015) Laura Rivino   Expert Review of Vaccines

Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial

(2015) Sarah L. George et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study

(2015) Chukiat Sirivichayakul et al.   JOURNAL OF INFECTIOUS DISEASES

CD8+T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate

(2015) Haiyan Chu et al.   JOURNAL OF INFECTIOUS DISEASES

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

(2015) Beth D. Kirkpatrick et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination

(2015) P. Robert Beatty et al.   Science Translational Medicine

Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity

(2015) Naphak Modhiran et al.   Science Translational Medicine

Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells

(2015) Amaryllis H. Van Craenenbroeck et al.   TRANSPLANTATION

Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study

(2015) Richard Rupp et al.   VACCINE

A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice

(2015) Taweewun Hunsawong et al.   VACCINE

Advances in aluminum hydroxide-based adjuvant research and its mechanism

(2015) Peng He et al.   Human Vaccines & Immunotherapeutics

Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial

(2014) Veerachai Watanaveeradej et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Animal models of viral hemorrhagic fever

(2014) Darci R. Smith et al.   ANTIVIRAL RESEARCH

Mechanism and Significance of Cell Type-Dependent Neutralization of Flaviviruses

(2014) S. Mukherjee et al.   JOURNAL OF VIROLOGY

Type I Interferon Signals in Macrophages and Dendritic Cells Control Dengue Virus Infection: Implications for a New Mouse Model To Test Dengue Vaccines

(2014) R. Zust et al.   JOURNAL OF VIROLOGY

The Human CD8+T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved Epitopes

(2014) Daniela Weiskopf et al.   JOURNAL OF VIROLOGY

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

(2014) Jorge E Osorio et al.   LANCET INFECTIOUS DISEASES

Evaluation of Dengue Virus strains for human challenge studies

(2014) M.P. Mammen et al.   VACCINE

Dengue Virus Neutralizing Antibody Levels Associated with Protection from Infection in Thai Cluster Studies

(2014) Darunee Buddhari et al.   PLoS Neglected Tropical Diseases

First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies

(2014) Jowin Kai Wei Ng et al.   PLoS Pathogens

Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera

(2014) Ruklanthi de Alwis et al.   PLoS Pathogens

Mouse Models to Study Dengue Virus Immunology and Pathogenesis

(2014) Raphaël M. Zellweger et al.   Frontiers in Immunology

A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial

(2013) Anna P. Durbin et al.   JOURNAL OF INFECTIOUS DISEASES

The global distribution and burden of dengue

(2013) Samir Bhatt et al.   NATURE

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

(2013) D. Weiskopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

(2013) Samuele Calabro et al.   VACCINE

Role of Humoral versus Cellular Responses Induced by a Protective Dengue Vaccine Candidate

(2013) Raphaël M. Zellweger et al.   PLoS Pathogens

A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults

(2012) Stephen J. Thomas et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines

(2012) W. Sun et al.   JOURNAL OF INFECTIOUS DISEASES

In vivo infection by a neuroinvasive neurovirulent dengue virus

(2012) Myriam Lucia Velandia-Romero et al.   JOURNAL OF NEUROVIROLOGY

Gamma Interferon (IFN- ) Receptor Restricts Systemic Dengue Virus Replication and Prevents Paralysis in IFN- /  Receptor-Deficient Mice

(2012) T. R. Prestwood et al.   JOURNAL OF VIROLOGY

Differential Targeting of Viral Components by CD4+ versus CD8+ T Lymphocytes in Dengue Virus Infection

(2012) L. Rivino et al.   JOURNAL OF VIROLOGY

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

(2012) Arunee Sabchareon et al.   LANCET

Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: Their immunity and protective efficacy in mice

(2012) Hui Lu et al.   MOLECULAR IMMUNOLOGY

Salmonella typhi Ty21a bacterial ghost vector augments HIV-1 gp140 DNA vaccine-induced peripheral and mucosal antibody responses via TLR4 pathway

(2012) Jing Wen et al.   VACCINE

The mechanism of action of MF59 – An innately attractive adjuvant formulation

(2012) D.T. O’Hagan et al.   VACCINE

Dengue Virus Infection-Enhancing Activity in Serum Samples with Neutralizing Activity as Determined by Using FcγR-Expressing Cells

(2012) Meng Ling Moi et al.   PLoS Neglected Tropical Diseases

Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Proinflammatory, Multifunctional T Cell Response in Humans

(2012) Janet C. Lindow et al.   PLoS Neglected Tropical Diseases

Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants

(2011) Veerachai Watanaveeradej et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans

(2011) Ming Qiao et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Critical issues in dengue vaccine development

(2011) Stephen J. Thomas et al.   CURRENT OPINION IN INFECTIOUS DISEASES

A Single Amino Acid in Nonstructural Protein NS4B Confers Virulence to Dengue Virus in AG129 Mice through Enhancement of Viral RNA Synthesis

(2011) D. Grant et al.   JOURNAL OF VIROLOGY

Dengue Virus Tropism in Humanized Mice Recapitulates Human Dengue Fever

(2011) Javier Mota et al.   PLoS One

Induction of a Protective Response in Mice by the Dengue Virus NS3 Protein Using DNA Vaccines

(2011) Simone M. Costa et al.   PLoS One

Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

(2011) Jorge E. Osorio et al.   VACCINE

Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant

(2011) Jaime Henrique Amorim et al.   VACCINE

Immunological and Viral Determinants of Dengue Severity in Hospitalized Adults in Ha Noi, Viet Nam

(2011) Annette Fox et al.   PLoS Neglected Tropical Diseases

Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue Disease

(2010) Raphaël M. Zellweger et al.   Cell Host & Microbe

The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity

(2010) Martina Beltramello et al.   Cell Host & Microbe

How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections

(2010) S. Ubol et al.   Clinical and Vaccine Immunology

CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after Vaccination

(2010) L. E. Yauch et al.   JOURNAL OF IMMUNOLOGY

IFN-  Receptor Signaling Regulates Memory CD8+ T Cell Differentiation

(2010) O. Sercan et al.   JOURNAL OF IMMUNOLOGY

Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans

(2010) W. Dejnirattisai et al.   SCIENCE

A Non Mouse-Adapted Dengue Virus Strain as a New Model of Severe Dengue Infection in AG129 Mice

(2010) Grace K. Tan et al.   PLoS Neglected Tropical Diseases

Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance

(2009) Stephen J. Thomas et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Dengue virus-induced hemorrhage in a nonhuman primate model

(2009) N. Onlamoon et al.   BLOOD

A Protective Role for Dengue Virus-Specific CD8+ T Cells

(2009) L. E. Yauch et al.   JOURNAL OF IMMUNOLOGY

The Medicinal Chemistry of Dengue Fever

(2009) Andrew J. Stevens et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cardif-Mediated Signaling Controls the Initial Innate Response to Dengue Virus In Vivo

(2009) S. T. Perry et al.   JOURNAL OF VIROLOGY

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

(2008) Bruno Guy et al.   VACCINE